Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update

SHELTON, Conn., Sept. 10, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today provided an update on the INVINCIBLE-4 trial. A pathological complete response ("pCR") has been observed in the first patient evaluated in Cohort A, where each patient receives two doses of INT230-6 eight days apart, followed by the SOC. To date, there has been favorable safety in cohort A. However, some patients in Cohort A experienced localized skin irritation near the tumor. As a result, new patient enrollment has been paused to evaluate the data collected and to implement necessary adjustments prior to reopening accrual.

Read more at prnewswire.com